Across Europe, cancer is increasingly becoming the leading cause of death, a trend projected to solidify by 2035. From Denmark and France to Ireland, the Netherlands, Norway, and the United Kingdom, the incidence of cancer is rising, placing immense strain on healthcare systems, and economies. A new report from the Institute for Health Economics (IHE) paints a stark picture: without significant and sustained investment in all facets of cancer care – from prevention and early detection to treatment and follow-up – Europe faces a future with 4.1 million new cancer cases and 2.1 million deaths by 2050. This underscores the urgent need for a comprehensive and proactive approach to combatting this growing public health crisis.
The IHE’s “Comparator Report on Cancer in Europe 2025” reveals a 60% increase in cancer diagnoses in Europe since 1995. Alarmingly, nearly one in two men and more than one in three women in the European Union will receive a cancer diagnosis before the age of 85. These statistics aren’t simply numbers; they represent a profound human cost and a growing economic burden. Prioritizing cancer research and treatment isn’t just a matter of public health, it’s a vital economic investment.
A Surge in Cancer Research and Innovative Therapies
Despite the rising incidence, the rate of cancer-related deaths isn’t increasing at the same pace, a testament to advancements in medical science. Improved treatments, earlier diagnoses, and better overall care are contributing to this positive trend. The IHE report highlights the boom in oncology research, noting that it has “driven the development of new drug classes in recent decades, and further breakthroughs are on the horizon.” The introduction of targeted therapies at the turn of the millennium and the Nobel Prize-winning immunotherapies in the 2010s have dramatically altered cancer treatment. Targeted therapies focus on the molecular vulnerabilities of cancer cells, while immunotherapies harness the body’s own immune system to fight the disease.
More recently, innovative approaches like antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), and CAR-T-cell therapies have expanded the therapeutic arsenal. The pace of innovation is accelerating, with nearly a third (29%) of all clinical trials worldwide now focused on oncology. The IHE anticipates further breakthroughs with new cell-based therapies, therapeutic cancer vaccines leveraging mRNA technology, proteolysis-targeting chimeras (PROTACs), gene editing, oncolytic virotherapy, and RNA interference.
The Preventable Burden: Reducing Risk Through Lifestyle and Public Health
While medical advancements offer hope, a significant portion of the cancer burden is preventable. Scientists estimate that 30 to 50% of worldwide cancer cases are linked to modifiable risk factors, including tobacco and alcohol consumption, obesity, unhealthy diets, physical inactivity, and infections with cancer-causing viruses like HPV and HBV, as well as bacteria like Helicobacter pylori. Addressing these factors through public health initiatives, health education, and preventative programs could substantially reduce the incidence of cancer across Europe.
The Economic Impact of Cancer: A Growing Cost
The financial toll of cancer is substantial and growing. The IHE reports that direct costs for cancer care in Europe more than doubled between 1995 and 2023, rising from €62 billion to €146 billion annually. While this increase largely mirrors the overall growth in healthcare spending, the economic impact remains significant. Indirect costs, such as lost productivity due to illness and premature death, have decreased somewhat due to improved treatments, but the combined direct and indirect costs rose by 43% from €159 billion to €228 billion over the same period.
Interestingly, the economic burden per new cancer patient has remained relatively constant, ranging from approximately €70,000 to €78,000 between 1995 and 2023, and even slightly decreasing in recent years. However, the sheer volume of new cancer diagnoses is driving up overall costs. The number of new cancer drugs entering the market has also increased dramatically, from an average of one per year between 1995 and 2000 to around 14 per year between 2021 and 2025, contributing to higher expenses. Despite these costs, the IHE data suggests that investment in cancer care is yielding positive returns.
The increasing investment in cancer research and treatment is crucial, but a holistic approach that prioritizes prevention and early detection is equally important. Addressing modifiable risk factors, strengthening healthcare systems, and fostering international collaboration will be essential to turning the tide against this pervasive disease. The future of cancer care in Europe hinges on a commitment to innovation, prevention, and equitable access to quality treatment for all.
Disclaimer: This article provides general information about cancer and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The IHE will continue to monitor cancer trends and economic impacts across Europe, with the next comprehensive report expected in 2028. Share your thoughts on this critical issue in the comments below, and help spread awareness by sharing this article.
Related reading
